-
Stifel Says Allergan Could Use A Face-Lift, Initiates Coverage With Hold
Tuesday, April 17, 2018 - 11:51am | 390Read More...The Street is largely bullish on Allergan plc (NYSE: AGN), but the firm caught an ambivalent critic Tuesday. The Rating Stifel Nicolaus analysts Annabel Samimy initiated coverage with a Hold rating and $192 price target. The Thesis By Stifel’s assessment, Allergan rests on the...
-
Endo To Enter A Year Of Recovery Following FDA Request To Pull Opana ER Off The Market
Friday, June 9, 2017 - 9:49am | 345Read More...Shares of Endo International plc - Ordinary Shares (NASDAQ: ENDP) were trading lower by more than 10 percent Friday morning in reaction to the U.S. Food and Drug Administration's request for the company to withdraw from the market its opioid painkiller called Opana ER. Stifel's Annabel Samimy felt...
-
Stifel Sees A Long Road To Stabilization At Valeant
Thursday, June 9, 2016 - 7:25am | 280Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) reported its 1Q16 results and reset its guidance once again. Stifel’s Annabel Samimy maintained a Buy rating for the company, while reducing the price target from $65 to $55. The analyst commented that although Valeant faces several challenges...
-
Report: Valeant More Likely To Sell Drugs Than Business Units
Tuesday, April 19, 2016 - 10:25am | 251Read More...Faced with $30 billion in debt, Valeant Pharmaceuticals Intl Inc (NYSE: VRX) has few options at its disposal. Among the company's options to reduce its debt load includes selling off some of its drug assets, or selling complete business units. According to a report by Reuters, Valeant is...
-
Valeant Perception Has Turned A Corner, Stifel Analysts Say
Monday, April 11, 2016 - 11:25am | 298Read More...Stifel’s Annabel Samimy reminded investors that Valeant Pharmaceuticals Intl Inc (NYSE: VRX)'s various franchises had meaningful brand value, while there was steady demand for its key products. The analyst maintained a Buy rating on Valeant Pharma, with a price target of $65....
-
Some On Wall Street Still Back Valeant
Tuesday, March 15, 2016 - 11:51am | 558Read More...Valeant Pharmaceuticals Intl Inc (NYSE: VRX) plunged 40 percent and touched a new 52-week low after the company reported a loss for its fourth quarter and slashed its outlook. The company cited incremental headwinds in Ophthalmology Rx, as well as the Commonwealth and Western Europe businesses...
-
Jazz Pharma Falls After Q4 Sales Miss Street View
Wednesday, February 24, 2016 - 4:39pm | 376Read More...Shares of Jazz Pharmaceuticals plc (NASDAQ: JAZZ) fell as much as 6 percent Wednesday after the company's fourth quarter revenue fell short of Street view. The company earned $1.32 a share for the fourth quarter. Excluding items, earnings were $2.60 a share, which came in line with analysts...
-
Stifel Reiterates Horizon Pharma As 'Select List' Pick, Sees 'Buying Opportunity In Multiple Misguided Reactions'
Wednesday, September 23, 2015 - 8:50am | 449Read More...Shares of Horizon Pharma PLC (NASDAQ: HZNP) have come under "inordinate pressure" in the last few days, according to Annabel Samimy of Stifel. Samimy maintained a Buy rating and $45 price target on the stock. According to Samimy, Horizon is "one of the stronger diversified...
-
Stifel Raises Valeant PT As Co. Continues To Execute Global Expansion Strategy
Thursday, April 30, 2015 - 9:54am | 239Read More...Stifel on Thursday issued a company report on Valeant Pharmaceuticals Intl Inc. (NYSE: VRX) after the company reported revenues of $2.19 billion and cash EPS of $2.36. Stifel rates Valeant Pharmaceuticals as a Buy and raised its price target from $230 to $250. Analyst Annabel Samimy wrote, "...
-
Firms Bullish On Valeant Following Earnings, Acquisition
Tuesday, February 24, 2015 - 2:44pm | 320Read More...Monday saw many biotech firms surging, among them was Valeant Pharmaceuticals Intl Inc (NYSE: VRX) after acquiring Salix Pharmaceuticals Ltd. (NYSE: SLXP). In Tuesday morning summaries, many firms lauded Valeant's earnings report. Of the different reasons for the increased price...
-
UPDATE: Stifel Downgrades Salix Pharmaceuticals As Uncovered Inventories Leaves Many Open Questions
Friday, November 7, 2014 - 9:15am | 180Read More...In a report published Friday, Stifel analyst Annabel Samimy downgraded the rating on Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) from Buy to Hold, and removed the $185.00 price target. In the report, Stifel noted, “SLXP reported 3Q14 mired in more wholesaler inventory issues, an audit, and a CFO...
-
Stifel Raises Price Target On Salix Pharmaceuticals, Ltd. On Possible Takeover
Wednesday, October 1, 2014 - 10:14am | 158Read More...Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) received a price target increase from $155 to $185 by Stifel, which maintained a Buy rating. Analyst Annabel Samimy noted their previous financial model assumed a tax inversion opportunity for the company. Changes in regulations at the Treasury...
-
UPDATE: Stifel Reiterates, Lowers Price Target On Egalet Corp As Filing Delay Is Likely
Wednesday, September 24, 2014 - 10:04am | 212Read More...In a report published Wednesday, Stifel analyst Annabel Samimy reiterated a Buy rating on Egalet Corp (NASDAQ: EGLT), but lowered the price target from $20.00 to $18.00. In the report, Stifel noted, “Egalet reported results from its 15mg PK study of Egalet-001 compared against MS-Contin, which just...
-
UPDATE: Stifel Downgrades Allergan as Company is Now on the Defensive
Monday, April 28, 2014 - 10:27am | 151Read More...In a report published Monday, Stifel analyst Annabel Samimy downgraded the rating on Allergan (NYSE: AGN) from Buy to Hold, and removed the $125.00 price target. In the report, Stifel noted, “In the midst of the Specialty Pharma M&A frenzy, we believed AGN's inactivity would eventually make...
-
UPDATE: Stifel Reiterates on Aerie Pharmaceuticals as Timelines Are on Track
Wednesday, March 19, 2014 - 8:12am | 165Read More...In a report published Wednesday, Stifel analyst Annabel Samimy reiterated a Buy rating on Aerie Pharmaceuticals (NASDAQ: AERI), and raised the price target from to $22.00 to $24.00. In the report, Stifel noted, “AERI reported 4Q13 revenue loss of $10.3mn translating to $0.62 loss-per-share with...
